Article

Former Alcon executive becomes Iridex president/CEO

Barry G. Caldwell joins Iridex Corp. as president and chief executive officer and as a member of the board of directors. He succeeds Theodore A. Boutacoff, who has been elected chairman of the board for Iridex.

Caldwell worked for Alcon Laboratories for more than 2 decades in numerous executive positions, including vice president of Alcon Canada as well as vice president and general manager of Alcon’s U.S. Surgical Division.

“His successful track record includes achievements in operating performance, strategic planning, mergers and acquisitions, and executing strategic initiatives-which resulted in profitable revenue growth,” Boutacoff said.

“With more than 30 years of experience in the ophthalmic sector and more than 20 years of tenure at Alcon, Barry has well-established relationships with physicians, industry executives, and key regulatory and legislative opinion leaders that will be beneficial to Iridex,” Boutacoff added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.